Infections After Chimeric Antigen Receptor T-Cell Therapy

Among over 2000 recipients of CAR-T therapy, respiratory viral infections occurred relatively late (but relatively often), whereas herpesvirus and fungal infections tended to occur earlier and less often.

Chimeric antigen receptor T-cell (CAR-T) therapy utilizes genetically modified autologous T cells to fight hematologic malignancies (mainly relapsed or refractory B-cell lymphoma [CD19-directed therapy]). Cytopenia, whether directly or indirectly caused by CAR-T therapy, can lead to immunodeficiency and consequent increased likelihood of opportunistic infections. To identify risk factors for infection and its temporal patterns, researchers retrospectively analyzed information from a global database (TriNetX) of patient records collected between 2017 and 2024. They reviewed the clinical course of 2256 patients receiving CAR-T therapy in the U.S. (83% of whom had received CD19-directed therapy).

Respiratory viral infections occurred in 23% of …

Reviewing Author

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Infections After Chimeric Antigen Receptor T-Cell Therapy

Topics

Reviewing Author